| LH |
Report |
Adjusted EPS (Q2 2026) |
BEAT |
pred ~$4.92 vs. cons $4.79 |
MEDIUM |
| LH |
Report |
Revenue (Q2 2026) |
BEAT |
pred ~$3.78B vs. cons $3.72B |
MEDIUM |
| LH |
Report |
Diagnostics organic revenue growth (Q2 2026) |
BEAT |
pred ~+5.5% vs. cons ~+4.5% |
LOW |
| LH |
Guide |
FY26 Adjusted EPS guide |
BETTER |
guide ~$17.90-$18.55 (mid ~$18.23) vs. cons ~$18.05 (FY2026) |
MEDIUM |
| LH |
Guide |
FY26 Enterprise revenue guide |
BETTER |
guide ~$14.75-$14.95B (mid ~$14.85B) vs. cons ~$14.78B (FY2026) |
MEDIUM |
| LH |
Guide |
BLS book-to-bill inflection |
BETTER |
pred ~1.02 vs. 0.94 prior quarter (Q2 2026) |
LOW |
| LH |
Guide |
FY26 Free cash flow guide |
UNCHANGED |
guide ~$1.24-$1.36B vs. cons ~$1.30B (FY2026) |
LOW |
| LH |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.0% |
— |
MEDIUM |
| LH |
Return |
5-day cumulative residual |
-5.0% (FADE) |
LH ripped ~13% in two weeks (and ~+45% off June lows) almost entirely on Quest read-through, so a beat-and-raise is largely priced; realized beta to SPX is ~0 (idiosyncratic move), meaning residual ≈ raw. Even with a clean beat, guide raise quality is modest (Q1 flow-through + FX) and the 2027 PAMA/RESULTS/CRUSH/ACA-subsidy overhang caps upward out-period revisions ahead of the Sept 10 Investor Day. Crowded long unwinds into a 'sell-the-news' — initial day-1 drop extends as estimates stabilize rather than ratchet higher. |
LOW |